Department of Neurology, Henry Ford Hospital, Detroit, Michigan, United States of America.
Celgene Cellular Therapeutics, Warren, New Jersey, United States of America.
PLoS One. 2014 Jan 21;9(1):e86621. doi: 10.1371/journal.pone.0086621. eCollection 2014.
Human Placenta-Derived Adherent Cells (PDAC®) are a novel mesenchymal-like cell population derived from normal human placental tissue. PDA-001 is a clinical formulation of PDAC® developed for intravenous administration. In this study, we investigated the efficacy of PDA-001 treatment in a rat model of transient middle cerebral artery occlusion (MCAo) in young adult (2-3 month old) and older rats (10-12 months old).
To evaluate efficacy and determine the optimal number of transplanted cells, young adult Wistar rats were subjected to MCAo and treated 1 day post MCAo with 1×10(6), 4×10(6) or 8×10(6) PDA-001 cells (i.v.), vehicle or cell control. 4×10(6) or 8×10(6) PDA-001 cells were also tested in older rats after MCAo. Treatment response was evaluated using a battery of functional outcome tests, consisting of adhesive-removal test, modified Neurological Severity Score (mNSS) and foot-fault test. Young adult rats were sacrificed 56 days after MCAo, older rats were sacrificed 29 days after MCAo, and lesion volumes were measured using H&E. Immunohistochemical stainings for bromodeoxyuridine (BrdU) and von Willebrand Factor (vWF), and synaptophysin were performed.
In young adult rats, treatment with 4×10(6) PDA-001 cells significantly improved functional outcome after stroke (p<0.05). In older rats, significant functional improvement was observed with PDA-001 cell therapy in both of the 4×10(6) and 8×10(6) treatment groups. Functional benefits in young adult and older rats were associated with significant increases in the number of BrdU immunoreactive endothelial cells, vascular density and perimeter in the ischemic brain, as well as significantly increased synaptophysin expression in the ischemic border zone (p<0.05).
PDA-001 treatment significantly improved functional outcome after stroke in both young adult and older rats. The neurorestorative effects induced by PDA-001 treatment may be related to increased vascular density and synaptic plasticity.
人胎盘源贴壁细胞(PDAC®)是一种新型的间充质样细胞群,来源于正常的人胎盘组织。PDA-001 是一种用于静脉给药的 PDAC®临床制剂。在这项研究中,我们在年轻成年(2-3 个月大)和老年大鼠(10-12 个月大)的短暂性大脑中动脉闭塞(MCAo)大鼠模型中研究了 PDA-001 治疗的疗效。
为了评估疗效并确定最佳移植细胞数量,年轻成年 Wistar 大鼠接受 MCAo 后,在 MCAo 后 1 天接受 1×10(6)、4×10(6)或 8×10(6)个 PDA-001 细胞(静脉注射)、载体或细胞对照治疗。MCAo 后也对 4×10(6)或 8×10(6)个 PDA-001 细胞进行了测试。治疗反应采用一系列功能结果测试进行评估,包括粘附去除测试、改良神经严重程度评分(mNSS)和足失误测试。年轻成年大鼠在 MCAo 后 56 天处死,老年大鼠在 MCAo 后 29 天处死,并使用 H&E 测量病变体积。进行溴脱氧尿苷(BrdU)和血管性血友病因子(vWF)以及突触素的免疫组织化学染色。
在年轻成年大鼠中,4×10(6)个 PDA-001 细胞治疗可显著改善中风后的功能结果(p<0.05)。在老年大鼠中,4×10(6)和 8×10(6)两个治疗组的 PDA-001 细胞治疗均观察到显著的功能改善。年轻成年和老年大鼠的功能获益与缺血性大脑中 BrdU 免疫反应性内皮细胞、血管密度和周长的显著增加以及缺血边界区突触素表达的显著增加相关(p<0.05)。
PDA-001 治疗可显著改善年轻成年和老年大鼠中风后的功能结果。PDA-001 治疗诱导的神经修复作用可能与血管密度增加和突触可塑性增强有关。